2.3 Neonatal Jaundice & Hyperbilirubinemia

Physiologic vs. Pathologic Jaundice

Neonatal jaundice, yellow discoloration of skin and sclera from bilirubin deposition, affects the majority of newborns to some degree and is usually unconjugated (indirect) hyperbilirubinemia arising from an immature hepatic conjugation pathway combined with a high neonatal red cell turnover. Physiologic jaundice typically appears after 24 hours of age, peaks around day 3-5 (day 5-7 in preterm infants) at a total serum bilirubin generally below 12-15 mg/dL, and resolves within 1-2 weeks. Pathologic jaundice is suggested by several exam-favorite red flags: jaundice appearing within the first 24 hours of life, a total bilirubin rising faster than expected (more than about 5 mg/dL per day, or crossing percentile lines on a standardized nomogram), a total bilirubin above the phototherapy threshold for the infant's age, or any elevation in conjugated (direct) bilirubin above 1 mg/dL or more than 20% of the total. Jaundice within the first 24 hours of life is never physiologic and always warrants urgent evaluation for hemolysis or infection.

Unconjugated vs. Conjugated Hyperbilirubinemia

Distinguishing unconjugated from conjugated hyperbilirubinemia focuses the differential diagnosis:

Conjugated hyperbilirubinemia is never physiologic and always requires prompt investigation — biliary atresia in particular is time-sensitive, since surgical outcomes with the Kasai portoenterostomy worsen sharply after 8 weeks of age. On examination, infants with conjugated hyperbilirubinemia often have dark urine and acholic (pale) stools, whereas unconjugated jaundice produces colorless urine and normally pigmented stools — a high-yield bedside clue to cholestasis that should trigger urgent hepatobiliary workup.

ABO and Rh Hemolytic Disease

Rh hemolytic disease occurs when an Rh-negative mother is sensitized to Rh-positive fetal red cells (typically from a prior pregnancy or bleed) and produces IgG anti-D antibodies that cross the placenta and hemolyze fetal or neonatal red cells; it can cause severe anemia and hydrops fetalis, and is now largely prevented by giving anti-D immunoglobulin to Rh-negative mothers at around 28 weeks gestation and again after delivery of an Rh-positive infant. ABO hemolytic disease occurs when a type O mother carries a type A or type B fetus. Unlike Rh disease, it can occur in a first pregnancy, because naturally occurring anti-A and anti-B IgG requires no prior sensitization, but it is usually milder, since A and B antigens are less densely expressed on fetal red cells. Both are evaluated with a direct antiglobulin (Coombs) test, evidence of hemolysis such as an elevated reticulocyte count or spherocytes on smear, and early-onset jaundice. G6PD deficiency, an X-linked enzymopathy common in Mediterranean, Middle Eastern, and African populations, can trigger acute hemolysis after oxidative stress (infection, certain drugs, or fava beans) and is a key cause of pathologic jaundice in male newborns that the Arab Board frequently tests.

Breastfeeding Jaundice vs. Breast-Milk Jaundice

These two entities are a classic exam discriminator:

The exam trap: breastfeeding itself should essentially never be stopped for either condition — supporting effective, continued breastfeeding is the correct answer far more often than "discontinue breastfeeding."

Bilirubin Nomograms and Phototherapy Thresholds

Management decisions use hour-specific total serum or transcutaneous bilirubin nomograms — the Bhutani nomogram for predischarge risk-of-progression screening, and current phototherapy and exchange-transfusion threshold curves — that plot bilirubin against postnatal age in hours, stratified by gestational age and the presence of neurotoxicity risk factors such as isoimmune hemolytic disease, G6PD deficiency, sepsis, significant lethargy, temperature instability, or a low serum albumin. Lower gestational age and the presence of risk factors both lower the treatment threshold substantially, so a 35-week infant with a risk factor is treated at a much lower bilirubin level than a healthy 40-week infant at the same postnatal age. As a general orientation rather than a substitute for reading the actual nomogram, phototherapy thresholds for a healthy term infant without risk factors are roughly in the 12-15 mg/dL range on day 1, rising to roughly 18-20 mg/dL by day 3-4, while a preterm or risk-factor-positive infant is treated several mg/dL lower at the same postnatal age.

Exchange Transfusion

Exchange transfusion is reserved for bilirubin levels that remain markedly elevated despite intensive phototherapy — roughly 4-5 mg/dL above the phototherapy threshold, or approaching levels associated with neurotoxicity — or for infants presenting with signs of acute bilirubin encephalopathy at any bilirubin level. When the total bilirubin comes within 2 mg/dL of the exchange threshold, this is treated as a medical emergency: the infant is escalated to intensive phototherapy with maximum irradiance and prepared for possible exchange. Exchange transfusion mechanically removes bilirubin and antibody-coated red cells far faster than phototherapy alone, which is particularly important in severe isoimmune hemolytic disease.

Kernicterus and Bilirubin Encephalopathy

Kernicterus, chronic and permanent bilirubin encephalopathy, results from deposition of unconjugated bilirubin in the basal ganglia and brainstem nuclei once bilirubin crosses the blood-brain barrier, typically at very high, prolonged unconjugated bilirubin levels (conjugated bilirubin is not neurotoxic in this way). Acute bilirubin encephalopathy presents in phases: early lethargy and poor feeding, progressing to hypertonia with retrocollis-opisthotonos and a high-pitched cry, and, if untreated, seizures and coma. Survivors of severe encephalopathy develop the classic chronic kernicterus tetrad: choreoathetoid cerebral palsy, upward gaze palsy, sensorineural hearing loss, and dental enamel dysplasia. Because kernicterus is largely preventable, the exam consistently rewards early recognition of risk factors — early-onset jaundice, hemolysis, prematurity — and timely phototherapy or exchange transfusion over delayed intervention.